Sara Kochanny
Papers
1
Total Citations
30
H-Index
1
About
Sara Kochanny is a leading clinical researcher in head and neck oncology, with a primary focus on human papillomavirus-associated oropharyngeal cancer (HPV+ OPC). Her work centers on developing innovative, de-escalated treatment strategies that maintain high cure rates while reducing long-term toxicity for patients. Kochanny’s major contribution is the OPTIMA II trial, a landmark study investigating the use of nivolumab, nab-paclitaxel, and carboplatin as induction therapy, followed by risk/response-adaptive locoregional treatment. This trial, which has garnered over 30 citations, represents a paradigm shift in the curative setting—demonstrating that immunotherapy can be effectively integrated early in treatment to allow for personalized, less intensive surgery or radiation. Her research addresses the critical need to balance excellent prognosis with quality of life, challenging conventional aggressive protocols. Kochanny’s work is highly influential among oncologists and trainees, offering a blueprint for future adaptive trials in HPV-driven cancers. Her achievements underscore a commitment to precision medicine and patient-centered outcomes, making her a key voice in the evolution of head and neck cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1